October 1, 2024 Investor Beware: Port Strike Puts Key Stocks And Sectors At Risk
September 30, 2024 Market Movers: Jobs Report and Key Earnings in Focus
September 19, 2024 Federal Reserve’s Aggressive Move Hints At Bold Economic Strategy
Apple: Lock In Gains Before They Evaporate
Tesla Stock: Too Many Unknowns After Robotaxi Event
Tesla: Time And Patience Running Out
The Biggest Problem With Nvidia’s Stock That Everyone Is Missing
October 3, 2024 Your Path to Profits: The Best Trading Platforms for New Traders
October 3, 2024 Mastering Trading Indicators: Your Essential Toolkit For Success
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
April 12, 2024 Improve Your Financial Status: A How-To Guide
Sorrento Therapeutics (SRNE) stock forecast for 2024
Updated: October 14, 2024 (04:57)
Sector: HealthcareThe share price of Sorrento Therapeutics, Inc. (SRNE) now
50/200 Day Moving Average: $ / $
This figure corresponds to the Average Price over the previous 50/200 days. For Sorrento Therapeutics stocks, the 50-day moving average is the support level today.
For Sorrento Therapeutics stocks, the 200-day moving average is the support level today.
Are you interested in Sorrento Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Sorrento Therapeutics stock price in 2024. How much will one Sorrento Therapeutics share be worth in 2024? Is it worth taking profit / loss on SRNE stock now or waiting? What are analysts' forecasts for Sorrento Therapeutics stock?
We forecast Sorrento Therapeutics stock performance using neural networks based on historical data on SRNE stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. This corporation stock prediction results are shown below and presented as a graph, table and text information.
Sorrento Therapeutics, Inc. stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Sorrento Therapeutics analysts is $. Today 200 Day Moving Average is the support level ( $). 50 Day Moving Average is the support level ( $).
Historical and forecast chart of Sorrento Therapeutics, Inc. stock
The chart below shows the historical price of Sorrento Therapeutics stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the SRNE stock price can be found in the table below.
Sorrento Therapeutics, Inc., a clinical stage Biopharma company, develops treatments for cancer, autoimmune, inflammatory and neurodegenerative diseases. She operates in two segments – Sorrento Therapeutics and Scilex. The company provides cancer therapists through the use of a proprietary r-monoclonal antibody antibody library and targeted delivery conditions that include chimeric antigen receptor T-cell therapy (car-T), dimeric antigen receptor T-cell therapy, and antibody-drug conjugates as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biological substances directly to the lymphatic system. In addition, the company’s clinical programs include anti-CD38 CAR-T therapy for the treatment of multiple myeloma as well as amyloidosis and graft versus host diseases. In addition, he is developing resiniferatoxin, a neopioid-based TRPV1 agonist neurotoxin for the treatment of advanced cancer and osteoarthritis of knee pain; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, the company is developing SEMDEXA, an injectable viscous gel formulation that is a Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system in clinical development for chronic low back pain. She has various collaborations with SmartPharm Therapeutics Inc. to develop a gene-encoded vaccine antibody to protect against COVID-19; Celularity, Inc. to initiate a Phase I / II clinical trial with up to 86 COVID-19 patients; and the Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, and a Research Trials Agreement with the University of Texas Medical Branch at Galveston for preclinical testing of Sorrento’s COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.
Sorrento Therapeutics (SRNE) Forecast for 2024
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Nov | 0.00 | 0.00 | 0.00 | 14.43 % |
| Dec | 0.00 | 0.00 | 0.00 | 22.00 % |
Sorrento Therapeutics information and performance
N/A
Market capitalization of the Sorrento Therapeutics, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of SRNE shares in the company outstanding by the market price of one share.
EBITDA of Sorrento Therapeutics is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Sorrento Therapeutics price target for 2024 by month
Target values for the price of one Sorrento Therapeutics share for Nov 2024.
In Nov, the Positive dynamics for Sorrento Therapeutics, Inc. shares will prevail with possible monthly volatility of 14.428% volatility is expected.
Pessimistic target level: 0.00
Optimistic target level: 0.00
Target values for the price of one Sorrento Therapeutics share for Dec 2024.
In Dec, the Positive dynamics for Sorrento Therapeutics, Inc. shares will prevail with possible monthly volatility of 22.002% volatility is expected.
Pessimistic target level: 0.00
Optimistic target level: 0.00
